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Abstract
Background: Pancreatic fistula (PF) remains a common source of morbidity following
pancreaticoduodenectomy (PD). Despite numerous studies, the optimal method of pancreatic remnant
reconstruction is controversial. This study examines the hypothesis that pancreaticogastrostomy (PG) is
associated with a lower risk for PF after PD compared with pancreaticojejunostomy (PJ).
Methods: Five electronic databases and the grey literature were searched for randomized controlled
trials (RCTs) comparing PJ and PG after PD. Two reviewers independently selected studies, extracted
data and assessed methodology. The primary outcome was the occurrence of PF of International Study
Group on Pancreatic Fistula (ISGPF) Grade B or C.
Results: Four RCTs including 676 patients were included. Pancreaticogastrostomy reduced the risk for
PF [relative risk (RR) 0.41, 95% confidence interval (CI) 0.21–0.62] without any difference between high-
and low-risk patients. Absolute risk reduction for PF was 4% (95% CI 2.4–5.6) in low-risk patients
compared with 10% (95% CI 6.5–14.8) in high-risk patients undergoing PG rather than PJ. The strength
of evidence for PF outcome was moderate according to the GRADE classification.
Conclusions: Reconstruction by PG decreases the rate of PF in comparison with PJ. Surgeons should
consider reconstructing the pancreatic remnant following PD with PG, particularly in patients at high risk
for PF.
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Introduction
Advances in pancreatic surgery techniques and perioperative care
have led to reduced mortality rates for pancreaticoduodenectomy
(PD) in high-volume expert centres.1,2 However, morbidity after
pancreatic resection remains high, with 30–60% of patients
experiencing complications following surgery, mainly as a result
of leak and subsequent fistula from the pancreatic anastomosis.2,3
Pancreatic reconstruction is particularly demanding; a variety
of methods and techniques have been proposed to maintain the
continuity of the anastomosis and diminish rates of leak.4–7 The
abundance of literature on this issue reflects the ongoing contro-
versy regarding the optimal method of pancreatic anastomosis.
The conventional anastomosis described for this operation is
pancreaticojejunostomy (PJ).8 Pancreaticogastrostomy (PG) has
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been described and studied as an alternative to jejunal anastomo-
sis in both observational studies and randomized controlled trials
(RCTs) with inconsistent results.9–11
Given the ongoing frequency of pancreatic leak or fistula and
the major morbidity associated with this complication, robust
evidence is needed to determine which reconstruction technique
yields better outcomes. Five systematic reviews and meta-analyses
have attempted to summarize the impact of PG compared with PJ
on the occurrence of pancreatic fistula (PF); however, most
included small numbers of RCTs among large numbers of obser-
vational studies, suffered from important methodological limita-
tions, lacked a consensus definition of PF and sensitivity analyses,
and failed to identify a significant benefit of either technique.10,12–14
More recently, two larger RCTs examining this important question
have been published.9,15 The present systematic review and meta-
analysis of RCTs was undertaken to examine the impact of PG
compared with that of PJ on PF in patients undergoing PD, and
to address methodological issues arising from previous
meta-analyses.
Materials and methods
This review was registered in PROSPERO (2013:
CRD42013005288).16
Search strategy
MEDLINE (1966 to August 2013), EMBASE (1974 to August
2013), the Cochrane Central Register for Controlled Trials, Web of
Knowledge, and the Scopus database (1966 to August 2013) were
systematically searched, with the help of an information specialist,
to identify potential RCTs, without language or other limitations.
The following search terms were used: (i) pancreatic dis$, pancre-
atic neo$, pancreas cancer, chronic pancreatitis, and (ii) pancrea-
tectomy, pancreatic resection, pancreaticojej$, pancreaticogas$,
pancreas reconstruction, and pancreas anast$. A standardized
filter was applied for RCTs. The grey literature (informally pub-
lished material not indexed in formal search engines) was
searched for unpublished results using the OpenSIGLE database,
Trip database, Google Scholar, and the database of registered trials
(http://www.clinicaltrials.gov). Bibliographies of all included
studies and previous narrative or systematic reviews were also
reviewed for relevant publications.
Two authors (FSWZ and RGD) independently selected studies,
extracted data and assessed the risk for bias. Disagreements were
resolved by consensus or by a third party (JH). A single reviewer
(JH) assessed the references from the grey literature.
Study selection
Explicit eligibility criteria allowed the inclusion of RCTs reporting
the effects on PF of PG compared with PJ PD. Studies including at
least 10 adults (aged ≥18 years) submitted to PD for benign or
malignant disease, and defining PF according to the International
Study Group on Pancreatic Fistula (ISGPF) definitions were eli-
gible.17 Studies that examined PD for trauma or acute pancreatitis
were excluded. Studies that included patients who did not meet
the present inclusion criteria were excluded if it was not possible
to distinguish those patients from the larger population. In the
event of duplicate publications, the most relevant and most
informative study was included.
Data abstraction
A standardized data extraction form was developed and pilot-
tested following the recommendations of the Cochrane Effective
Practice and Organization of Care Review Group.18 The following
patient characteristics were collected: age; gender, and indication
for surgery. The corresponding author for each study was con-
tacted to obtain additional details about missing or incomplete
data when this was deemed necessary. Pancreas-associated risk
was categorized based on baseline risk for PF when possible, as
reported by the authors in the original manuscript as: (i) high risk
for PF (soft gland or small pancreatic duct), or (ii) low risk for PF
(hard gland or large pancreatic duct).
Outcome measures
The primary outcome was the occurrence of clinically significant
PF defined as Grade B or C fistula based on the ISGPF classifica-
tion.17 Secondary outcomes included operating time (min), esti-
mated blood loss (ml), bile leak, delayed gastric emptying (DGE),
postoperative bleeding (divided into intraluminal and
extraluminal bleeding), 30-day postoperative major morbidity
(Clavien–Dindo Grades III and IV) and mortality, and length of
stay (LoS) (days).19–21
Risk for bias assessment
The methodological quality of included studies was evaluated
using a checklist of key methodological components derived from
the CONSORT (consolidated standards of reporting trials) state-
ment rather than by using a summary score.22–25 The GRADE
(grading of recommendations assessment, development and
evaluation) system was used to present a summary of findings and
rate the overall strength of evidence.26 The robustness of included
RCTs that reported a significant difference in PF favouring PG was
assessed by computing the Fragility Index (FI). This index assesses
the minimum number of patients that are required to switch from
non-event (no PF) to event (PF) in the group with fewer events
(PG) in order to reverse statistical significance.27 Thus, it evaluates
how many patients in the PG group would have needed to experi-
ence a PF for the difference between PG and PJ to become
non-significant.
Statistical analysis
Descriptive statistics were presented as means and standard devia-
tions (SDs) for continuous variables, and as proportions with 95%
confidence intervals (95% CIs) for dichotomous variables. When
studies presented medians and ranges, the mean and SD were
estimated using the method of Hozo et al.28 Meta-analysis was
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conducted using Review Manager (RevMan) Version 5.2.5
(Cochrane Collaboration, Copenhagen, Denmark) for each
outcome with data in two or more studies. The data were pooled
for each outcome using random-effects models. The relative risk
(RR) with 95% CI was calculated for dichotomous outcomes.
Absolute risk reduction (ARR) in PF with PG was computed using
the pooled RR for risk reduction and PF rate with PJ for baseline
risk. The standard mean difference (95% CI) was used for con-
tinuous variables.18 The I2 statistic was used to assess the extent of
heterogeneity.29 The following a priori hypotheses were generated
to explain heterogeneity in results: (i) study design (single-centre
versus multicentre studies); (ii) population (high- versus low-risk
pancreas, and malignant versus benign indications for surgery);
(iii) intervention (duct-to-mucosa PJ versus a ‘fish-mouth’ PJ
technique), and (iv) intervention (pancreatic stent versus no
stent). Publication bias was assessed visually by creating a funnel
plot for each outcome for which data were available from five or
more trials.18
The review was conducted and results reported in accordance
with the PRISMA (preferred reporting items for systematic
reviews and meta-analyses) statement.30
Results
Systematic search
Four RCTs enrolling a total of 676 patients were included
(Fig. 1).9,15,31,32
Searches of the grey literature and of the references of included
studies did not identify additional citations. One additional refer-
ence was identified after the initial electronic search in the table of
contents of a surgical journal, and included in the analysis.15
Description of included studies
All studies were published in English between 2008 and 2013 and
included between 108 and 329 patients (Table 1). Study tech-
niques and postoperative management protocols are presented in
Table 2.
Key methodological elements are summarized in Table 3. The
FIs of the studies reporting a significant benefit were 2 (n = 108),31
6 (n = 329),9 and 5 (n = 123).15
Primary outcome: pancreatic fistula
Rates of PF varied from 18% (n = 10/55) to 33% (n = 19/58) in the
PJ control groups, and from 11% (n = 12/108) to 21% (n =
26/123) in entire cohorts. Patients undergoing PG had a signifi-
cantly lower risk for PF than patients who underwent PJ (RR 0.41,
95% CI 0.27–0.62) (Fig. 2). The funnel plot did not show con-
vincing asymmetry. The strength of evidence supporting risk
reduction in PF with PG was moderate (Table 4).
In studies that did not report the use of pancreatic stents, the
summary estimate was similar (RR 0.46, 95% CI 0.12–1.79) but
non-significant and was associated with greater heterogeneity
(I2 = 58%). Finally, an analysis of only multicentre trials revealed
a significant reduction in PF with PG (RR 0.38, 95% CI 0.23–0.61;
I2 = 0%), compared with a non-significant result for single-centre
trials (RR 0.46, 95% CI 0.12–1.76; I2 = 56%).
Secondary outcomes
One study used a consensus definition for DGE and one used
Clavien–Dindo classifications to report morbidity. No significant
difference was observed in secondary outcomes between PG and
PJ (Figs 3 and 4). None of the funnel plots for secondary outcomes
showed convincing asymmetry. The quality of evidence was low
for all secondary outcomes (Table 4).
Discussion
This study systematically reviewed and pooled data from four
RCTs investigating the impacts of PG compared with PJ on PF.
Based on evidence of moderate quality, PG is associated with a
lower occurrence of PF (RR 0.41, 95% CI 0.27–0.62), but no
significant differences emerged in biliary leak, DGE, postopera-
tive bleeding, major morbidity, mortality or LoS. When only
high- or low-risk pancreas groups were considered, there was no
difference in RR. However, when baseline risks for PF were
Figure 1 Study selection conducted in line with PRISMA (preferred
reporting items for systematic reviews and meta-analyses)
guidelines
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considered, ARR was greater in patients with a high-risk pan-
creas (10%) compared with those with a low-risk pancreas (4%),
which indicates that PG offers more critical benefits in high-risk
patients.
The proposed technical and physiological advantages of PG
over PJ have been discussed in several studies reporting the
technique.34–38 The anastomosis may be facilitated by a thick
gastric wall, can rely on an excellent gastric blood supply, and is
subject to less tension as a result of the anatomic proximity of the
pancreatic remnant to the posterior gastric wall. Lack of
enterokinase in the gastric remnant may prevent the activation of
pancreatic enzymes, thereby avoiding both damage to the anasto-
mosis itself and the repercussions associated with potential PF. A
nasogastric tube may be used to decompress the stomach and
relieve tension on the anastomosis immediately after surgery, and
can eventually be reinserted to deal with ileus or manage a leak
without percutaneous intervention. Finally, PG can be accessed
endoscopically for instrumentation if needed, and is located away
from major vessels skeletonized during resection, which may
theoretically mitigate the risk for vascular damage by proteolytic
pancreatic enzymes in the event of PF. Retrospective studies have
raised concerns regarding increased intraluminal bleeding and
compromised longterm pancreas exocrine function with PG.12
Although this analysis revealed no difference in the overall risk for
Table 1 Populations and clinical characteristics of the included studies
Study Study period Population characteristics High-risk
pancreas
n (%)Sample,
n
Pancreatic
cancer
n (%)
Age, years old,
mean (SE or
range)
Fernández-Cruz et al.31
2008
Spain
2005–2007 108 PG: 26 (49%)
PJ: 28 (51%)
PG: 63 (13)
PJ: 63 (14)
PG: 24 (45%)
PJ: 25 (45%)
Wellner et al.32
2012
Germany
2006–2011 116 PG: 26 (44%)
PJ: 30 (53%)
PG: 67 (34–84)
PJ: 64 (23–81)
PG: 35 (59%)
PJ: 29 (51%)
Topal et al.9
2013
Belgium
2009–2012 329 PG: 98 (61%)
PJ: 107 (64%)
PG: 67 (61–73)
PJ: 66 (59–75)
PG: 98 (60%)
PJ: 102 (61%)
Figueras et al.15
2013
Spain
2008–2012 123 PG: 55 (85%)
PJ: 49 (84%)
PG: 67 (35–80)
PJ: 66 (42–80)
PG: 34 (52%)
PJ: 33 (57%)
PG, pancreatogastrostomy; PJ, pancreatojejunostomy; SE, standard error.
Table 2 Surgical management in the included studies
Study Surgical technique Postoperative
management
Surgeons,
n
PJ technique PG technique Pylorus-preserving
n (%)
Use of stent Use of
drain
Prophylactic
octreotide
Fernández-Cruz
et al.31
2008
NR 2 layers
Duct-to-mucosa
End-to-side
2 layers
Duct-to-mucosa
To bottom of gastric
partition
PG: 53 (100%)
PJ: 55 (100%)
Yes, internal Yes No
Wellner et al.32
2012
3 2 layers
Duct-to-mucosa
2 layers
Dunking
To posterior gastric
wall
PG: 52 (88%)
PJ: 55 (96%)
Yes, external
(only for PJ)
Yes Yes, selectivea
Topal et al.9
2013
NR Layers based on
surgeon decision
Dunking
End-to-side
Layers based on
surgeon decision
Dunking
To posterior gastric
wall
PG: 98 (60%)
PJ: 102 (61%)
No Yes Yes, all
Figueras et al.15
2013
3 2 layers
Duct-to-mucosa
2 layers
Dunking
To posterior gastric
wall
PG: 30 (46%)
PJ: 28 (48%)
NR Yes No
aInformation from referenced publication.33
PG, pancreatogastrostomy; PJ, pancreatojejunostomy; NR, not reported.
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postoperative bleeding, patterns appeared to differ among those
experiencing it, with more intraluminal events with PG and more
extraluminal events with PJ. The former occurs early in the post-
operative course and is theoretically more easily managed than the
latter, which can potentially represent a devastating delayed result
of PF. Because of the very small number of patients experiencing
bleeding overall, no significant difference could be detected. Addi-
tional concerns regarding the longterm outcomes and durability
of PG have also been voiced. Although it was not a specific
outcome of this review, one RCT assessed exocrine pancreatic
function and identified poorer function with PJ.15 Interestingly,
some have suggested that PJ anastomotic stricture resulting from
PF is associated with pancreatic insufficiency, which may explain
this finding.39
A soft pancreas and small pancreatic ducts have been associated
repeatedly with significantly higher rates of PF. The trials included
in this meta-analysis included pancreases of both low and high
risk, resulting in a heterogeneous population in terms of baseline
risk. Although the RR did not change when high- or low-risk
pancreas subgroups were considered, the ARR was larger for
patients with a high-risk pancreas (10% versus 4%) submitted to
PG rather than PJ as a result of the considerable differences in
baseline risk for PF. This highlights the more pronounced benefits
of PG on PF in the context of a high-risk pancreas.
Some potential differences between PG and PJ may not be
obvious in the current analysis as a result of the heterogeneous
nature of the studied population. Firstly, there are potential nega-
tive impacts of PG compared with PJ on postoperative manage-
ment, mainly arising from the need for nasogastric tube
decompression if the stomach fills with pancreatic secretions and
the subsequent delay in oral intake, and the routine use of surgical
drains. As a result, PG may potentially be associated with a longer
LoS. No difference in LoS was observed in this meta-analysis.
Mean lengths of stay were quite long (range: 12–16 days), indicat-
ing that the studies included were probably conducted before the
adoption of ‘fast-track’ protocols, when postoperative nasogastric
tubes, surgical drains and delayed oral intake were routine for all
patients.40,41 It is possible that with contemporary clinical path-
ways and enhanced recovery after surgery protocols, patients sub-
mitted to PG and not experiencing a leak would have a longer LoS
than those with PJ who are fast-tracked through the postoperative
course. Nevertheless, the reduction of PF obviously takes priority
over a potentially longer LoS. Secondly, despite the reduction in
PF, DGE, morbidity and mortality did not differ between patients
submitted to PG and PJ, respectively. With regard to DGE, this
may also be explained by the heterogeneity of the population,
whereby the lower rate of PF in PG balances out a potentially
higher occurrence of DGE in this group. Given the smaller ARR in
Table 3 Assessment of methodology
Study Setting Timing of
randomization
Stratification of
randomization
Allocation
concealment
Blinding Standardization
of technique
Pancreatic
fistula
measure
Fernández-Cruz
et al.31
2008
Single centre Before surgery No No NR Yes ISGPF
Wellner et al.32
2012
Single centre During surgery, before
reconstruction
No No NR Yes ISGPF
Topal et al.9
2013
Multiple centres During surgery, before
reconstruction
Yes (pancreas
duct size)
Yes No No ISGPF
Figueras et al.15
2013
Multiple centres During surgery, before
reconstruction
Yes (diagnosis
and centre)
Yes NR Yes ISGPF
NR, not reported; ISGPF, International Study Group on Pancreatic Fistula.
Figure 2 Comparison of the occurrence of pancreatic fistula after pancreaticogastrostomy (PG) with that after pancreaticojejunostomy (PJ).
IV, inverse variance; 95% CI, 95% confidence interval
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PF associated with the use of PG in a low-risk pancreas, PG may
not appear to be best suited to use in this context. However,
because of the larger ARR associated with PG in patients with a
high-risk pancreas, the benefits of reducing PF outweigh the
potential drawbacks of the technique. Hence, a selective approach
to the use of PG after PD based on the baseline risk for PF may be
advisable in order to maximize the benefits of the technique. New
tools that enable the surgeon to appreciate a patient’s risk for PF,
such as the fistula risk score, are now available and may help in
implementing this selective use of PG.42
Among previous meta-analyses, two observed a significant
benefit of PG on the occurrence of PF10,12 and three did not.13,14,43
However, with one exception, these previous studies suffered from
important methodological limitations, including a search strategy
limited to one or a few electronic databases of material published
only in English, the absence of systematic methodological assess-
ment, the lack of sensitivity analyses to explore the heterogeneity
of results, and the inclusion of a large number of observational
studies, along with a few RCTs.12–14,31 A meta-analysis by McKay
et al. used sound methodology, but included only one RCT.10
Therefore, the pooling of previous data to examine the impacts of
PG versus PJ on PF was limited by the inclusion of data from
inherently biased observational studies. The present meta-analysis
is the first to include only RCTs and to observe a significant
reduction in PF with PG. It also offers insights into the differences
in results through an exploration of heterogeneity and subgroup
analyses, leading to a detailed practical proposal for the transfer of
results into practice in order to maximize the benefits of selecting
the use of PG in patients with a high-risk pancreas.
Although meta-analyses offer increased power to detect treat-
ment effects by synthesizing the results of individual studies, they
remain limited by the quality of the studies included and the
heterogeneity of results. The weaknesses of this study refer to the
methodological limitations of the studies included, most of which
are related to allocation concealment and blinding, which are
known limitations of surgical RCTs.44,45 Nevertheless, the
summary of the findings of this study indicates that conclusions
on the primary outcome of PF are based on evidence of moderate
quality. The FI analysis shows that at least two of the three trials
reporting a benefit for PG are robust, with indices of 5 and 6.9,15,31
This index indicates that the results are unlikely to be changed by
the transforming of only a few events (of PF) into non-events (of
no PF) and thus can be relied upon. Such a finding is closely
related to sample size: studies with larger sample sizes are less
prone to fragile results in which the significance of the measure of
effect can be modified by the transformation of only one or two
events into non-events.
The strengths of this systematic review and meta-analysis
include a comprehensive, systematic and highly selective search
conducted without restriction for language or types of publication,
which also considered the grey literature and was performed in
duplicate. The studies included were rigorously evaluated using a
Table 4 GRADE summary of findings for the effect of pancreaticogastrostomy versus pancreaticojejunostomy for reconstruction after
pancreaticoduodenectomy
Outcome Participants,
n (studies, n)
Illustrative comparative risk Summary measure
(95% CI)a
Absolute risk
reduction
(95% CI)b
Quality of
evidence
(GRADE)cPG PJ
Clinically significant
pancreatic fistula
1133 (4) 8% (28/339) 20% (69/337) RR 0.41 (0.27–0.62) +++ Moderate
Among high-risk pancreas 69 (2) 11% (15/133) 24% (32/131) 10% (6.5–14.8) +++ Moderate
Among low-risk pancreas 180 (2) 5% (4/87) 9% (8/93) 4% (2.4–5.6) ++ Low
Operative time (min) 676 (4) – – SMD 0.01 (−0.22 to 0.25) – ++ Low
Estimated blood loss (ml) 560 (3) – – SMD 0.20 (−0.12 to 0.53) ++ Low
Biliary leak 231 (2) 0.8% (1/118) 6% (7/113) RR 0.18 (0.03–1.07) ++ Low
Delayed gastric emptying 676 (4) 18% (60/339) 13% (45/337) RR 1.23 (0.70–2.16) ++ Low
Postoperative bleeding 676 (4) 12% (41/339) 9% (29/337) RR 1.39 (0.89–2.17) ++ Low
Extraluminal bleedingd 32 (3) 50% (10/20) 92% (11/12) RR 0.65 (0.41–1.04) ++ Low
Intraluminal bleedingd 30 (2) 58% (11/19) 9% (1/11) RR 3.79 (0.87–16.91) ++ Low
Major postoperative
morbidity
437 (2) 52% (112/215) 55% (123/222) RR 0.78 (0.40–1.53) ++ Low
Postoperative mortality 676 (4) 2% (8/339) 4% (12/337) RR 0.66 (0.27 −1.6) ++ Low
Length of stay (days) 676 (4) – – SMD −0.31 (−1.03 to 0.42) ++ Low
aValues of <1 favour PG.
bValues are the expected difference in absolute risk if patients undergo PG instead of PJ.
cQuality rated from + (very low) to ++++ (very high).
dData reported among the subgroup of patients with postoperative bleeding.
PG, pancreaticogastrostomy; PJ, pancreaticojejunostomy; 95% CI, 95% confidence interval; RR, relative risk; SMD, standard mean difference.
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checklist of key methodological elements drawn from a consensus
statement on RCTs, GRADE quality of evidence classification, and
the FI to assess the robustness of positive results. The primary
outcome chosen was based on a consensus definition, was
common,was significant in terms of clinical repercussions,and was
important to patients. Results of a priori sensitivity analyses were
provided in order to give insight into the heterogeneity of results.
Conclusions
This study observed that PG is associated with a lower risk for PF
compared with PJ. This benefit appeared to be greater in high-risk
patients. Surgeons should consider reconstructing the pancreatic
remnant following PD with PG, particularly in patients at high
risk for PF.
Figure 3 Comparisons of the occurrences of biliary leak, delayed gastric emptying, postoperative morbidity (Clavien–Dindo Grades III and
IV) and postoperative mortality after pancreaticogastrostomy (PG) with occurrences after pancreaticojejunostomy (PJ). M–H, Mantel–
Haenszel method; IV, inverse variance; 95% CI, 95% confidence interval
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